Arsenal Biosciences
Latest round
- Series C
Last raised
- Jul 2024
Total raised
- $631M
Investors
- 20
About Arsenal Biosciences
Founded in 2019 and headquartered in San Francisco, US, Arsenal Biosciences, Inc. develops cell therapies for cancer treatment. The company was established by Ken Drazan (CEO), Kole Roybal, Nicholas Haining, John Wherry, Alexander Marson, and Brad Bernstein. In July 2024, Arsenal Biosciences, Inc.65 billion post-money. Arsenal Biosciences, Inc. specializes in developing programmable cell therapies aimed at tackling solid tumors in cancer patients. The company's primary innovation lies in its proprietary technology that enables the engineering of T cells to target and destroy cancer cells. ArsenalBio assembles a diverse team of experts across multiple scientific disciplines to create therapies that enhance patient outcomes, focusing on the complex nature of solid tumors. Their products are primarily aimed at clinical institutions and healthcare providers in North America and Europe, catering to oncologists and healthcare systems that require advanced treatment options for cancer patients. Arsenal Biosciences operates on a revenue model driven by partnerships and collaborations with pharmaceutical companies and research institutions. Revenue is generated through transactional agreements where ArsenalBio provides its cell therapy technologies to partners, resulting in payments and potential royalties based on product performance and sales, particularly for flagship therapies developed under the AB-4000 series. The company plans to innovate tools and processes for developing new candidate cell therapies. ArsenalBio is also targeting expansion into new geographic markets, furthering its reach to enhance distribution of its innovative therapies.
Who invested in Arsenal Biosciences
20 investors across 3 rounds
See all investors in Arsenal Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Arsenal Biosciences
Who invested in Arsenal Biosciences?
Arsenal Biosciences has 20 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Arsenal Biosciences raised?
Arsenal Biosciences has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Arsenal Biosciences last raise money?
Arsenal Biosciences's most recent round on record is a Series C, in Jul 2024.
What does Arsenal Biosciences do?
Founded in 2019 and headquartered in San Francisco, US, Arsenal Biosciences, Inc.
Where is Arsenal Biosciences headquartered?
Arsenal Biosciences is headquartered in South San Francisco, US.
Which VCs invest in companies like Arsenal Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Arsenal Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Arsenal Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.